RVMDRevolution Medicines, Inc.Signing up patients
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Non-small Cell Lung Cancer (NSCLC) · Colorectal Cancer (CRC) · Pancreatic Ductal Adenocarcinoma (PDAC) · Advanced Solid Tumors
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 754 (planned)
- Started
- May 31, 2022
- Main results expected
- May 31, 2027
- Fully finished
- Jul 26, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signs
Measured over: up to 2.5 years
Number of Participants with Dose-Limiting Toxicity (DLT)
Measured over: 21 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05379985 · record last updated 2026-05-15 · checked 2026-11-09 15:47 UTC